Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1865-8652
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Erratum to: Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users ; volume:32 ; number:4 ; day:17 ; month:4 ; year:2015 ; pages:387 ; date:4.2015
Advances in therapy ; 32, Heft 4 (17.4.2015), 387, 4.2015
- Creator
-
Laliberté, François
Cloutier, Michel
Crivera, Concetta
Nelson, Winnie W.
Olson, William H.
Schein, Jeffrey
Vanderpoel, Julie
Germain, Guillaume
Lefebvre, Patrick
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-015-0202-8
- URN
-
urn:nbn:de:101:1-2019080321591392156944
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Laliberté, François
- Cloutier, Michel
- Crivera, Concetta
- Nelson, Winnie W.
- Olson, William H.
- Schein, Jeffrey
- Vanderpoel, Julie
- Germain, Guillaume
- Lefebvre, Patrick
- SpringerLink (Online service)
Other Objects (12)
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Non-valvular Atrial Fibrillation (NVAF) Patients with Diabetes in a US Population
Effect of Rivaroxaban Versus Warfarin on Health Care Costs Among Nonvalvular Atrial Fibrillation Patients: Observations from Rivaroxaban Users and Matched Warfarin Users
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Anticoagulation with warfarin and rivaroxaban ameliorates experimental autoimmune encephalomyelitis
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
Rivaroxaban versus warfarin for the management of left ventricle thrombus
Effectiveness and Safety of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Concomitant Obstructive Sleep Apnea
Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin
Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Postthrombotic Syndrome in Patients Treated With Rivaroxaban or Warfarin for Venous Thromboembolism
Long-term survival in venous thromboembolic disease: rivaroxaban vs. warfarin – propensity score matching study